ER, Good find on the Clinical Trials update on NA
Post# of 148280
Good find on the Clinical Trials update on NASH. For quick reference for anyone who wishes to investigate the update, the link below should show the latest 2 updates side-by-side. Additions are in green and edits/deletions are in red with strikeouts.
https://clinicaltrials.gov/ct2/history/NCT045...udyPageTop
Since safety is at the forefront now with regard to the hold, I looked at SAEs.
For 700 mg Leronlimab, there were two SAEs: eye infection bacterial and invasive ductal breast carcinoma.
For 350 mg Leronlimab, there was one SAE: death based on car accident not believed related to treatment.
From a layman's perspective, that looks like a good record. Nice to see them continuing to take care of business.